|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Federal grants | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Loss on conversions and change in fair value of convertible notes | |||||
| Other income (expense): | |||||
| Change in fair value of liability classified warrants | |||||
| Interest expense, net | |||||
| Other income and expense, net | |||||
| Total other income (expense), net | |||||
| Net loss | |||||
| Net loss attributable to noncontrolling interests | |||||
| Deemed dividend related to warrants down round provision | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders, basic | |||||
| Net loss per share attributable to common stockholders, diluted | |||||
| Weighted average common shares outstanding, basic | |||||
| Weighted average common shares outstanding, diluted | |||||
Loading...
